Abbott ACT I Carotid Stent Clinical Trial

Abbott Vascular ACT I is a prospective, randomized, multi-center trial that is enrolling a maximum of 1,658  patients, at up to 50 sites in North America.

ACT I is designed to demonstrate the non-inferiority of CAS when compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid artery disease (CAD) in people at normal risk for surgery.

ACT I is using Abbott Vascular Emboshield BareWire Rapid Exchange Embolic Protection System with the Xact Rapid Exchange Carotid Stent System.

Read more...

Abbott ACT I Carotid Stent Clinical Trial

Abbott Vascular ACT I is a prospective, randomized, multi-center trial that is enrolling a maximum of 1,658  patients, at up to 50 sites in North America.

ACT I is designed to demonstrate the non-inferiority of CAS when compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid artery disease (CAD) in people at normal risk for surgery.

ACT I is using Abbott Vascular Emboshield BareWire Rapid Exchange Embolic Protection System with the Xact Rapid Exchange Carotid Stent System.

Read more...

Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Stifel Raises Micrus Endovascular Target to $19

Following a meeting with Micrus management where they came away positive on the prospects of Micrus managing to achieve its stated revenue guidance of $84-87 million for fiscal 2010, Stifel Analysts raised their target to $19 from $15. They also indicated that Micrus will be able to drive significant operating margin improvement throughout the remainder of year.

Read more...

Stifel Raises Micrus Endovascular Target to $19

Following a meeting with Micrus management where they came away positive on the prospects of Micrus managing to achieve its stated revenue guidance of $84-87 million for fiscal 2010, Stifel Analysts raised their target to $19 from $15. They also indicated that Micrus will be able to drive significant operating margin improvement throughout the remainder of year.

Read more...

Palmisano: Neuro Intervention Market is $1 Billion

Robert Palmisano Estimates $950 Mil Neurovascular Intervention Market for the year 2010.

Announcement was made at JPMorgan Healthcare Conference later today (January 12th 2009).

Read more...